Leading the Way in Life Science Technologies

GEN Exclusives

More »

BioPerspectives

Mar 29, 2007

Ten Years After Dolly: Where Are We?

  • It has been more than ten years since the birth of a lamb named Dolly jolted the scientific world. Dolly was the first mammal to be cloned from an adult somatic cell. Ian Wilmut, Ph.D., was the head of the team at the Roslin Institute that carried out the research that led to the arrival of that forever famous sheep.

    In this week’s podcast, Dr. Wilmut explains why the birth of Dolly was so significant. He talks about the original scientific impetus for the cloning of Dolly and discusses why many of the scientific benefits that should result from knowledge gained from studying Dolly have yet to be realized. Dr. Wilmut also explores those areas of scientific research that have shown demonstrable advancement as a result of work with Dolly.

    Dr. Wilmut offers advice on how scientists should respond to critics who say that the birth of Dolly contained the element of a Frankenstein factor. He notes that the creation of cloned animals, especially primates, remains a difficult task, and provides some suggestions on what needs to be done to increase the efficiency rate of successful and healthy animal clones.

    For anyone working in the biotech or pharmaceutical industries, this is a must listen!

    After listening, return to the blog and give your thoughts on the following question:

    Somatic cell cloning for disease research has not advanced as far as many had expected post-Dolly. Which aspects of somatic cell cloning technology need to be significantly improved before the scientific benefits of the technique can be fully realized?



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »